戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 spital, Division of Pharmacoepidemiology and Pharmacoeconomics.
2  levels and reinforces the need to undertake pharmacoeconomic analyses and choose therapies from a lo
3                                              Pharmacoeconomic analyses of chemotherapeutic options co
4 rappreciated effects are recent clinical and pharmacoeconomic analyses that show worse outcomes in pa
5 e of the different costs of the antifungals, pharmacoeconomic analysis is required to identify the mo
6                    Pharmacoepidemiologic and pharmacoeconomic analysis of health care databases has b
7                               We conducted a pharmacoeconomic analysis to determine whether the alter
8                                  To describe pharmacoeconomics and its relationship to drug intervent
9 f IVIG, combined with a dose-finding effect, pharmacoeconomics, and quality-of-life assessments, are
10                                              Pharmacoeconomics appear to play a dominant role in rheu
11         Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital. Departm
12 ogy, pharmacokinetics, pharmacodynamics, and pharmacoeconomics complements the expertise of other mem
13                     But to some extent these pharmacoeconomic concerns are amplified in myeloma due t
14 pofol; benzodiazepines; intensive care unit; pharmacoeconomics; critical illness
15 of its cost-effectiveness, leveraging recent pharmacoeconomic data from Italy.
16 s, enables generation of clinically relevant pharmacoeconomic data while providing comprehensive view
17 intervention is prohibitive, as supported by pharmacoeconomic data, commentary might be provided.
18 so widely variable and there is a paucity of pharmacoeconomic data, the JTFPP generally does not cons
19 so widely variable and there is a paucity of pharmacoeconomic data, the JTFPP generally does not cons
20 tiveness analysis, the preferred approach to pharmacoeconomic evaluation today.
21                                              Pharmacoeconomic evaluations are crucial to the optimal
22                                              Pharmacoeconomic evaluations are increasingly important
23 toid arthritis, there is growing interest in pharmacoeconomic evaluations in other rheumatic diseases
24 of the chronic nature of rheumatic diseases, pharmacoeconomic evaluations must be carried out over su
25   The critical assessment and utilization of pharmacoeconomic evaluations, always in context with cur
26 o measure both the clinical efficacy and the pharmacoeconomic impact of implementing, as standard of
27 g with associated increases in mortality and pharmacoeconomic impact.
28                                              Pharmacoeconomics is assuming an increasingly important
29                                              Pharmacoeconomics is the branch of economics which appli
30 in contemporary oncology practice, driven by pharmacoeconomic issues, patient convenience, and the po
31        We conclude by highlighting available pharmacoeconomic models for antibacterial discovery and
32 The purpose of this study was to compare the pharmacoeconomics of liposomal versus conventional thera
33    We examine current myeloma therapy from a pharmacoeconomic perspective, and discuss the costs invo
34                                          The pharmacoeconomic principles that drive oral drug formula
35 both device and drug manufacturers regarding pharmacoeconomic, safety, and efficacy issues.
36 sions about a sponsor's proprietary agent in pharmacoeconomic studies.
37        Long-term functional and, ultimately, pharmacoeconomic, studies in elderly persons are indicat
38                          Our results provide pharmacoeconomic support for the use of lamivudine proph
39   This choice could depend on their relative pharmacoeconomic value.